U.S. Department of Defense
FDA Office of Orphan Products Development
Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021
Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib
21 Ha'arba'a Street
Tel Aviv 6473921
972 3 541 3131
PER IHUB MGMT
DISCLAIMER: ONLY FOR MICK
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
|RDHL News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)||07/12/2022 08:04:16 AM|
|RDHL News: RedHill Announces New H. pylori and COVID-19 Data Publication and Presentations at Leading Upcoming Scientific Conferences||07/12/2022 08:00:00 AM|
|RDHL News: Securities Registration: Employee Benefit Plan (s-8)||06/27/2022 09:30:37 AM|
|RDHL News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)||06/23/2022 07:08:17 AM|
|RDHL News: RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22||06/23/2022 07:00:00 AM|